Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Assessing evidence from clinical trials in chronic hepatitis C.

B R Bacon1

  • 1Division of Gastroenterology and Hepatology, Saint Louis University Liver Center, Saint Louis University School of Medicine, St Louis, MO 63110, USA. baconbr@slu.edu

Journal of Viral Hepatitis
|April 25, 2006
PubMed
Summary

Hepatitis C treatment faces challenges with current therapies causing side effects and non-response. New experimental drugs are in development, requiring physicians to understand clinical trial design and evidence evaluation for chronic hepatitis C.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study.

Journal of viral hepatitis·2016
Same author

Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network.

Journal of viral hepatitis·2016
Same author

Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin.

Alimentary pharmacology & therapeutics·2013
Same author

Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy.

Alimentary pharmacology & therapeutics·2010
Same author

Clinical trial: randomized controlled study of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol.

Alimentary pharmacology & therapeutics·2008
Same author

Iron absorption and hepatic iron uptake are increased in a transferrin receptor 2 (Y245X) mutant mouse model of hemochromatosis type 3.

American journal of physiology. Gastrointestinal and liver physiology·2006

Area of Science:

  • Hepatology
  • Clinical Trial Design
  • Viral Hepatitis Research

Background:

  • Hepatitis C presents significant global morbidity and mortality.
  • Current combination therapy (interferon and ribavirin) has limitations, including poor tolerability and a rising number of non-responders.
  • A substantial pipeline of experimental drugs for chronic hepatitis C is under development.

Purpose of the Study:

  • To familiarize physicians with critical issues in clinical trial design for hepatitis C.
  • To equip healthcare providers with strategies for interpreting evidence from hepatitis C clinical trials.
  • To address the challenges posed by non-responders to existing hepatitis C treatments.

Main Methods:

  • The supplement reviews key aspects of clinical trial design in the context of hepatitis C.

Related Experiment Videos

  • It discusses methodologies for evaluating evidence derived from clinical trials for chronic hepatitis C.
  • Focus is placed on understanding the outcomes of experimental hepatitis C therapies.

    • Main Results:

    • Recent therapeutic advances show sustained virologic remission rates exceeding 50% in some cases.
    • However, limitations in current treatment regimens necessitate novel approaches.
    • The development of new drugs aims to improve treatment efficacy and tolerability for hepatitis C.

    Conclusions:

    • Physicians must understand clinical trial design to effectively evaluate new hepatitis C treatments.
    • Interpreting evidence from clinical trials is crucial for managing chronic hepatitis C.
    • The ongoing research and development of experimental drugs offer hope for improved hepatitis C management.